• Rotigotine Workflows for Dopamine Research

  2026-08-26

  Build more interpretable Parkinson’s disease research workflows with Rotigotine, from receptor-proximal cell assays to continuous-exposure animal models. This guide connects concentration selection, formulation control, neuroprotection readouts, and troubleshooting for a dopamine D2/D3 receptor agonist with broader dopaminergic activity.

• Protease Inhibitor Cocktail EDTA-Free: K1010 Guide

  2026-08-25

  Protease Inhibitor Cocktail EDTA-Free K1010 is a 100X DMSO concentrate for broad protease control during protein extraction and sample preparation. Its EDTA-free formulation supports workflows that require divalent cations, including phosphorylation-sensitive and kinase assays, but it does not replace phosphatase inhibitors or assay-specific validation.

• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-08-24

  Discover how an EDTA-Free Protease Inhibitor can protect OXPHOS, LRPPRC, and signaling readouts from pre-analytical degradation. This guide connects inhibitor selection with Western blot, Co-IP, and cancer-metabolism assay design.

• Protease Inhibitor Cocktail EDTA-Free: K1010

  2026-08-24

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit degradation of proteins during extraction and sample preparation while avoiding EDTA-related chelation. It is appropriate for lysates used in Western blotting, co-immunoprecipitation, pull-down, immunostaining, and phosphorylation-sensitive assays, but it should not be treated as a complete metalloprotease or phosphatase-control solution.

• EIF4A3–circEIF2S2 Axis in Colorectal Cancer

  2026-08-23

  The reference study identifies an EIF4A3–circEIF2S2–miR-646–UHMK1 regulatory axis that links circular RNA biogenesis to colorectal cancer growth, metastasis, and immune suppression. Its combination of expression profiling, loss-of-function studies, rescue experiments, immune co-culture, and xenograft models provides a mechanistic framework for evaluating circEIF2S2 as a disease-relevant biomarker and therapeutic target.

• DIDS Workflows for Chloride and Tumor Assays

  2026-08-22

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) connects chloride-transport pharmacology with experimentally useful models of cell stress, vascular signaling, and tumor response. This guide emphasizes controlled workflows, vehicle and solubility checks, and assay designs that separate channel effects from the broader consequences of impending cell death.

• IGF2BP1–THBS1–TLR4 Axis in Pulmonary Fibrosis

  2026-08-21

  This 2025 study identifies an m6A-dependent IGF2BP1–THBS1–TLR4 pathway that links macrophage glycolytic reprogramming with fibrotic polarization in pulmonary fibrosis. Its knockdown, rescue, and metabolic experiments provide a mechanistic framework for studying how macrophage state influences lung injury and extracellular-matrix remodeling.

• EGCG Nanoparticles Enhance FLASH Radiotherapy

  2026-08-20

  A 2026 study reports that functionalized, self-assembled EGCG nanoparticles (BENPs) can increase the oxidative and DNA-damaging effects of FLASH radiotherapy while promoting antitumor immune responses. The work combines cell viability, DNA damage, immunofluorescence, animal efficacy, immune profiling, RNA sequencing, and biosafety analyses to evaluate a radiosensitization strategy.

• Substance P: From Mechanism to Translational Strategy

  2026-08-20

  Substance P is a tachykinin neuropeptide that connects CNS signaling with pain transmission, inflammation, and immune response modulation. This thought-leadership article outlines how translational teams can turn its NK-1 receptor biology into more reproducible assays while applying lessons from spectral-interference research without overstating cross-domain evidence.

• Sisomicin Activity Against Clinical Isolates

  2026-08-19

  Stewart and Bodey evaluated sisomicin against 565 clinical isolates and found strong in vitro activity against most Gram-negative bacilli, with modest advantages over gentamicin and tobramycin for selected species. The study also exposed cross-resistance among related aminoglycosides, while identifying amikacin as a potentially useful option for many resistant isolates.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-08-19

  This study identifies circulating soluble GPNMB as a mechanistic and clinically useful marker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By combining plasma GPNMB, CAF-epithelial niche features, and clinicopathological variables, the authors developed a multimodal model with potential value for precision immunotherapy selection.

• Ponicidin Targets Lin28B/Let-7/PBK in TNBC

  2026-08-18

  A 2026 European Journal of Medicinal Chemistry study identifies ponicidin as a candidate inhibitor of the Lin28B/Let-7 axis in triple-negative breast cancer. Its integrated computational, biochemical, cellular, and animal-model evidence connects Lin28B binding with Let-7 restoration, PBK suppression, apoptosis, and reduced tumor growth, while also defining important limitations for translation.

• Pepstatin A for Reliable Cell Assays

  2026-08-18

  Learn how Pepstatin A (SKU A2571) can help researchers separate aspartic-protease biology from confounding changes in cell viability, proliferation, and cytotoxicity readouts. This scenario-based guide covers mechanism, formulation, dosing, orthogonal validation, and practical supplier selection.

• Macrophage EP4 Loss Accelerates Atherosclerosis

  2026-08-17

  The reference study identifies macrophage EP4 deficiency as a driver of atherosclerosis progression, linking receptor loss to CD36-dependent lipid uptake, foam-cell formation, and M1 polarization. Its combination of genetically defined mice, oxLDL-stimulated macrophages, transcriptomics, proteomics, Western blotting, and qPCR provides a mechanistic framework for interpreting how inflammatory and lipid-handling programs converge in plaque disease.

• Protease Inhibitor Cocktail for Metabolic Assays

  2026-08-17

  Learn how a Protease Inhibitor Cocktail can protect metabolic assay readouts from degradation without chelating divalent cations. This guide uses ANGPTL4–LPL research to connect sample preservation with stronger decisions in Western blotting, activity assays, and protein extraction.

556 records 7/38 page Previous Next First page 上5页 678910 下5页 Last page